Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HL-085 plus vemurafenib in BRAF V600E-mutant advanced or metastatic non-small cell lung cancer
CTR20231191Phase 2Active
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib, vemurafenib in non-small cell lung cancer (NSCLC), sponsored by Shanghai KeChow Pharmaceuticals. Started Feb 2024; status: active.
02
Drugs
tunlametinibvemurafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231191.